Fragment library design: Efficiently hunting drugs in chemical space

Drug Discovery Today: Technologies

Volumn 7, Issue 3, 2010, Pages

  Boyd, Susan M ^a   De Kloe, Gerdien E ^b  

^a ST JOHN S COLLEGE   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL PRODUCT;

ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; MOLECULAR DOCKING; PHYSICAL CHEMISTRY; PUBLICATION;

EID: 78650754832     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2010.11.010     Document Type: Review

References (85)

1. G.E. de Kloe Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discov. Today 14 2009 630 646
2. G. Chessari, and A.J. Woodhead From fragment to clinical candidate - a historical perspective Drug Discov. Today 14 2009 668 675
3. M. Congreve Recent developments in fragment-based drug discovery J. Med. Chem. 51 2008 3661 3680
4. C. Abad-Zapatero, and J.T. Metz Ligand efficiency indices as guideposts for drug discovery Drug Discov. Today 10 2005 464 469
5. P.J. Hajduk Fragment-based drug design: How big is too big? J. Med. Chem. 49 2006 6972 6976
6. G. Siegal Integration of fragment screening and library design Drug Discov. Today 12 2007 1032 1039
7. M. Coles NMR-based screening technologies Drug Discov. Today 8 2003 803 810
8. U.H. Danielson Fragment library screening and lead characterization using SPR biosensors Curr. Top. Med. Chem. 9 2009 1725 1735
9. P.J. Hajduk One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules J. Am. Chem. Soc. 119 1997 12257 12261
10. M.J. Hartshorn Fragment-based lead discovery using X-ray crystallography J. Med. Chem. 48 2005 403 413
11. K. Retra Development of SPR biosensor assays for primary and secondary screening of AChBP ligands Anal. Biochem. 407 2010 58 64
12. T. Hesterkamp, and M. Whittaker Fragment-based activity space: smaller is better Curr. Opin. Chem. Biol. 12 2008 260 268
13. C. Lipinski, and A. Hopkins Navigating chemical space for biology and medicine Nature 432 2004 855 861
14. A. Schuffenhauer Library design for fragment based screening Curr. Top. Med. Chem. 5 2005 751 762
15. G.V. Paolini Global mapping of pharmacological space Nat. Biotechnol. 24 2006 805 815
16. C.G. Wermuth Selective optimization of side activities: another way for drug discovery J. Med. Chem. 47 2004 1303 1314
17. G.W. Bemis, and M.A. Murcko The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 39 1996 2887 2893
18. G.W. Bemis, and M.A. Murcko Properties of known drugs. 2. Side chains J. Med. Chem. 42 1999 5095 5099
19. J. Fejzo The SHAPES strategy: an NMR-based approach for lead generation in drug discovery Chem. Biol. 6 1999 755 769
20. C.A. Lepre Fragment-based lead discovery and optimization using the SHAPES strategy Abst. Papers Am. Chem. Soc. 230 2005 U2762 U12762
21. C.A. Lepre Applications of SHAPES screening in drug discovery Comb. Chem. High Throughput Screen. 5 2002 583 590
22. J.M. Moore Applications of NMR SHAPES screening in drug discovery Abst. Papers Am. Chem. Soc. 221 2001 U38 U138
23. X.Q. Lewell RECAP - retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry J. Chem. Inform. Comput. Sci. 38 1998 511 522
24. Ajay Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules? J. Med. Chem. 41 1998 3314 3324
25. M. Feher, and J.M. Schmidt Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry J. Chem. Inform. Comput. Sci. 43 2003 218 227
26. A.K. Ghose A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases J. Comb. Chem. 1 1999 55 68
27. J. Sadowski, and H. Kubinyi A scoring scheme for discriminating between drugs and nondrugs J. Med. Chem. 41 1998 3325 3329
28. P.J. Hajduk Privileged molecules for protein binding identified from NMR-based screening J. Med. Chem. 43 2000 3443 3447
29. J. Klekota, and F.P. Roth Chemical substructures that enrich for biological activity Bioinformatics 24 2008 2518 2525
30. D. Rognan Chemogenomic approaches to rational drug design Br. J. Pharmacol. 152 2007 38 52
31. D.M. Schnur Are target-family-privileged substructures truly privileged? J. Med. Chem. 49 2006 2000 2009
32. J.J. Sutherland Chemical fragments as foundations for understanding target space and activity prediction J. Med. Chem. 51 2008 2689 2700
33. A. Schreyer, and T. Blundell CREDO: a protein-ligand interaction database for drug discovery Chem. Biol. Drug Des. 73 2009 157 167
34. S. Danishefsky On the potential of natural products in the discovery of pharma leads: A case for reassessment Nat. Product Rep. 27 2010 1114 1116
35. P.D. Dobson 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries Drug Discov. Today 14 2009 31 40
36. C.M. Dobson Chemical space and biology Nature 432 2004 824 828
37. D.R. Davies Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography J. Med. Chem. 52 2009 4694 4715
38. P. Ertl Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds J. Med. Chem. 49 2006 4568 4573
39. W.R. Pitt Heteroaromatic rings of the future J. Med. Chem. 52 2009 2952 2963
40. A. Schuffenhauer The scaffold tree - visualization of the scaffold universe by hierarchical scaffold classification J. Chem. Inform. Model. 47 2007 47 58
41. T. Fink Virtual exploration of the small-molecule chemical universe below 160 daltons Angew. Chem. Int. Ed. 44 2005 1504 1508
42. T. Fink, and J.L. Reymond Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery J. Chem. Inform. Model. 47 2007 342 353
43. L.C. Blum, and J-L. Reymond 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13 J. Am. Chem. Soc. 131 2009 8732 8733
44. J. Hert Quantifying biogenic bias in screening libraries Nat. Chem. Biol. 5 2009 479 483
45. J. Venhorst Design of a high fragment efficiency library by molecular graph theory Med. Chem. Lett. 1 2010 499 503
46. M. Geitmann Interaction kinetic and structural dynamic analysis of ligand binding to acetylcholine-binding protein Biochemistry 49 2010 8143 8154
47. A.J. Thompson An efficient and information rich biochemical method design for fragment library screening on ion channels Biotechniques 49 2010 822 829
48. M. Congreve A rule of three for fragment-based lead discovery? Drug Discov. Today 8 2003 876 877
49. M.M. Hann, and T.I. Oprea Pursuing the leadlikeness concept in pharmaceutical research Curr. Opin. Chem. Biol. 8 2004 255 263
50. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
51. J. Xu, and J. Stevenson Drug-like index: a new approach to measure drug-like compounds and their diversity J. Chem. Inform. Comput. Sci. 40 2000 1177 1187
52. A.L. Hopkins Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
53. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890
54. M.L. Verdonk, and D.C. Rees Group efficiency: a guideline for hits-to-leads chemistry Chemmedchem 3 2008 1179 1180
55. C. Abad-Zapatero Ligand efficiency indices for effective drug discovery Expert Opin. Drug Discov. 2 2007 469 488
56. D.E. Patterson Neighborhood behavior: a useful concept for validation of molecular diversity descriptors J. Med. Chem. 39 1996 3049 3059
57. J. Xu A new approach to finding natural chemical structure classes J. Med. Chem. 45 2002 5311 5320
58. C. Catana Simple idea to generate fragment and pharmacophore descriptors and their implications in chemical informatics J. Chem. Inform. Model. 49 2009 543 548
59. S. Sciabola Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability J. Chem. Inform. Model. 47 2007 76 84
60. P.J. Ballester, and W.G. Richards Ultrafast shape recognition for similarity search in molecular databases Proc. R. Soc. A: Math. Phys. Eng. Sci. 463 2007 1307 1321
61. J.A. Haigh Small molecule shape-fingerprints J. Chem. Inform. Model. 45 2005 673 684
62. M.M. Hann Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inform. Comput. Sci. 41 2001 856 864
63. A.R. Leach Fragment screening: an introduction Mol. Biosyst. 2 2006 430 446
64. K. Babaoglu, and B.K. Shoichet Deconstructing fragment-based inhibitor discovery Nat. Chem. Biol. 2 2006 720 723
65. C.P. Mpamhanga One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening J. Med. Chem. 52 2009 4454 4465
66. J. Tsai Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U. S. A. 105 2008 3041 3046
67. S.S. Antonysamy Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors Bioorg. Med. Chem. Lett. 18 2008 2990 2995
68. G.M. Rishton Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening Curr. Opin. Chem. Biol. 12 2008 340 351
69. Edink, E.S. et al. The heat is on: thermodynamic analysis in fragment-based drug discovery. Drug Discov. Today Technol. (this issue)
70. A.D. Scott Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors Chemmedchem 4 2009 1985 1989
71. I.D. Kuntz The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 96 1999 9997 10002
72. R. Morphy, and Z. Rankovic Fragments, network biology and designing multiple ligands Drug Discov. Today 12 2007 156 160
73. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
74. D.G. Teotico Docking for fragment inhibitors of AmpC beta-lactamase Proc. Natl. Acad. Sci. U. S. A. 106 2009 7455 7460
75. H.T. Ji Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors J. Am. Chem. Soc. 130 2008 3900 3914
76. N. Baurin Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets J. Chem. Inform. Comput. Sci. 44 2004 2157 2166
77. I.J. Chen, and R. Hubbard Lessons for fragment library design: analysis of output from multiple screening campaigns J. Comput. Aid. Mol. Des. 23 2009 603 620
78. A.M. Petros Discovery of a potent inhibitor of the antiapoptotic protein Bcl-x(L) from NMR and parallel synthesis J. Med. Chem. 49 2006 656 663
79. J.S. Albert An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes Curr. Top. Med. Chem. 7 2007 1600 1629
80. G.L. Card A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design Nat. Biotechnol. 23 2005 201 207
81. A. Kuglstatter Tyramine fragment binding to BACE-1 Bioorg. Med. Chem. Lett. 18 2008 1304 1307
82. Y-S. Wang Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors J. Med. Chem. 53 2009 942 950
83. S.K. Burley Application of FAST (TM) fragment-based lead discovery and structure-guided design to discovery of small molecule inhibitors of BCR-ABL tyrosine kinase active against the T315I imatinib-resistant mutant Blood 106 2005 206a
84. N. Baurin Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds J. Chem. Inform. Comput. Sci. 44 2004 643 651
85. C.A. Lepre Library design for NMR-based screening Drug Discov. Today 6 2001 133 140